|
|
|
|
|
PEER-TO-PEER. CLINICAL CONVERSATIONS |
|
|
|
|
|
| Examining the Role of Docetaxel with Radiation Therapy and ADT in Non-Metastatic Prostate Cancer |
Phillip Kantoff, MD and Anthony D’ Amico, MD, PhD
Phillip Kantoff and Anthony D’Amico join Alicia Morgans highlighting a randomized controlled trial examining the role of docetaxel with radiation therapy and androgen deprivation therapy in men with non-metastatic unfavorable-risk prostate cancer that Dr. D’Amico presented at the ASCO 2021 annual meeting. |
|
|
|
|
|
|
|
|
|
|
| The Effect of Mandated Bone Protective Agents on Fracture Risk With Longer Follow-Up (EORTC 1333 / PEACE III Trial) |
| Fred Saad, MD, FRCS |
| The randomized phase III EORTC-1333-GUCG also known as the PEACE-III trial, compares enzalutamide vs a combination of Radium 223 and enzalutamide in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients. At the 2021 ASCO annual meeting, an updated analysis of fracture incidence with longer follow-up of the phase III PEACE-III trial was presented. In this conversation with Charles Ryan, Fred Saad highlights this data confirming the early fracture rate results. |
|
|
|
|
|
|
|
|
|
|
|
| Determining Dose-Limiting Toxicity and Maximum Tolerated Dose of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer |
| Scott Tagawa, MD |
| Scott Tagawa joins Alicia Morgans in a discussion on a Phase I study evaluating the tolerability of 225Ac-J591 in metastatic castration-resistant prostate cancer. Dr. Tagawa discusses data he presented at the American Society of Clinical Oncology 2021 meeting, including the overall combined results, longer follow-up, as well as increased numbers of PSA responses, CTC count changes, and adverse events. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights from the 2021 American Society of Clinical Oncology Annual Meeting |
|
|
|
| Oral Abstract Session - Prostate |
| A Phase 3 Trial with a 2x2 Factorial Design of Abiraterone Acetate plus Prednisone and/or Local Radiotherapy in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC): First Results of PEACE-1 |
| Karim Fizazi, MD |
| Karim Fizazi presented the first results of the PEACE-1 trial assessing the role of the combination of abiraterone acetate with prednisone and local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer. The Prostate Cancer Consortium in Europe (PEACE) is an academic, European program. |
|
|
|
|
|
| SWOG S1216: A Phase III Randomized Trial Comparing ADT Plus TAK-700 With ADT Plus Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer |
| Neeraj Agarwal, MD |
| Neeraj Agarwal presented the first results of the SWOG S1216 trial assessing TAK-700 in patients with metastatic hormone-sensitive prostate cancer. Despite clinically meaningful improvement in various outcome measures with Tak + ADT over ADT + bicalutamide in men with mHSPC, the improvement in OS did not meet the pre-specified criteria for statistical significance. |
|
|
|
|
|
|
|
|
|
|
| Decreased Fracture Rate by Mandating Bone Protecting Agents in the EORTC 1333/PEACEIII Trial Combining Ra223 with Enzalutamide Versus Enzalutamide Alone: An Updated Safety Analysis |
| Silke Gillessen, MD |
| Silke Gillessen presents updated safety results from the EORTC 1333 / PEACE III trial of radium-223 and enzalutamide, specifically examining the effect of mandated bone protective agents on fracture risk with longer follow-up. |
|
|
|
|
|
| Can We Define the Standard of Therapy for First-Line Metastatic Hormone-Sensitive Prostate Cancer? - Discussion |
| Lisa Horvath, MBBS, Ph.D. |
| Following three presentations regarding novel treatment approaches for first-line treatment of patients with metastatic hormone-sensitive prostate cancer in the Prostate, Testicular, and Penile Oral Abstract session at the 2021 American Society of Clinical Oncology Annual Meeting, Dr. Lisa Horvath provided a discussant overview of these data and the rapidly moving disease space of metastatic hormone-sensitive prostate cancer. |
|
|
|
|
|
| Ancestral Characterization of the Genomic Landscape, Comprehensive Genomic Profiling Utilization, and Treatment Patterns May Inform Disparities in Advanced Prostate Cancer: A Large-Scale Analysis |
| Brandon Mahal, MD |
| Brandon Mahal presented a comprehensive analysis encompassing genomic analysis and assessment of treatment patterns to better understand disparities in advanced prostate cancer. This large analysis demonstrated largely similar rates of actionable gene alterations for men of African and European ancestry. As a result, intrinsic biologic differences are unlikely to explain observed differences in racial outcomes for men with prostate cancer. |
|
|
|
|
|
| Association of Increased Intensity of Prostate-Specific Antigen Screening in Younger African American Men With Improved Prostate Cancer Outcomes |
| Edmund Qiao, BS |
| Edmund Qiao presented an assessment of the association between prostate cancer screening intensity with prostate specific antigen (PSA) testing with prostate cancer outcomes in younger African American men diagnosed with prostate cancer. |
|
|
|
|
|
| A Prospective Validation of the Genomic Classifier To Define High-Metastasis Risk in a Subset of African American Men With Early Localized Prostate Cancer: VanDAAM Study |
| Kosj Yamoah, MD, Ph.D. |
| kosj Yamoah presented the results of the VanDAAM study, a prospective study validating the genomic classifier to identify patients with a high risk of metastasis among African American men with early localized prostate cancer. To do so, the authors performed a multisite, prospective validation trial of the genomic classifier (Decipher score) in African American men. Patients with low and intermediate risk prostate cancer were recruited, though those undergoing active surveillance were ineligible. |
|
|
|
|
|
| Poster Discussion Session - Prostate |
| Phase I Study of 225Ac-J591 for Men with mCRPC |
| Scott T. Tagawa, MD |
| Scott Tagawa presented results of a dose-escalation plus expansion cohort of a first in human study of 225Ac-J591. The hypothesis is that mAb J591 will be able to deliver a potent alpha emitter to tumors without dose-limiting toxicity to other organs. |
|
|
|
|
|
| Novel Approaches to Metastatic Prostate Cancer: Are We Making Progress? |
| Julie Graff, MD |
| The 2021 ASCO annual meeting’s poster discussion session for prostate cancer included a discussant presentation by Dr. Julie Graff discussing novel approaches to metastatic prostate cancer. Dr. Graff states that, she does believe that we are making progress with novel approaches in metastatic prostate cancer, and encourages clinicians to enroll patients in these important early phase clinical trials. |
|
|
|
|
|
| Sabizabulin (VERU-111), an Oral Cytoskeleton Disruptor, To Treat Men With mCRPC Who Failed an Androgen Receptor Targeting Agent |
| Mark C. Markowski, MD, Ph.D. |
| Mark Markowski presented results of the phase 1b/2 clinical study establishing the maximum tolerated dose and evaluating the preliminary efficacy in men with mCRPC also resistant to androgen receptor targeting agents. This phase 1b/2 clinical trial demonstrates that oral daily dosing of sabizabulin (VERU-111) has a favorable safety profile and that chronic dosing is feasible. |
|
|
|
|
|
| CheckMate 9KD Cohort A1 Final Analysis: Nivolumab + Rucaparib for Post-Chemotherapy mCRPC |
| Russell K. Pachynski, MD |
| Russell Pachynski presented the final results for cohort A1 (nivolumab + rucaparib for post-chemotherapy mCRPC) of CheckMate 9KD. Cohort A1 enrolled patients with post-chemotherapy mCRPC (1–2 prior taxane regimens), ongoing ADT, ≤ 2 prior novel hormonal therapies (abiraterone, enzalutamide, etc) for mCRPC, and no prior PARP inhibitor treatment. |
|
|
|
|
|
| Pembrolizumab Plus Enzalutamide for Enzalutamide-Resistant mCRPC: Updated Analyses After One Additional Year of Follow-Up From Cohorts 4 and 5 of the KEYNOTE-199 Study
|
| Julie Graff, MD
|
| Julie Graff presented results of the updated efficacy and safety data after an additional 1 year of follow-up of the KEYNOTE-199 study. After more than 30 months of follow-up data, pembrolizumab + enzalutamide continued to show modest and durable antitumor activity among patients with mCRPC who became resistant to enzalutamide.
|
|
|
|
|
|
| Evaluation of PSA Progression After Initiation of Enzalutamide or Abiraterone: Real-World Data on mCRPC |
| Fernando López-Campos, MD |
| Fernando López-Campos evaluated the significance of an early PSA increase in mCRPC patients treated with enzalutamide or abiraterone. PSA progression at 4 weeks after enzalutamide or abiraterone is significantly associated with shorter OS and may help identify patients not benefitting from enzalutamide or abiraterone before clinical or radiographic progression. PSA pattern progression and its association with OS might differ depending on the drug used (enzalutamide or abiraterone). |
|
|
|
|
|
| Talazoparib, an Oral PARP Inhibitor for Men With mCRPC and DNA Damage Response Alterations: Detailed Safety Analyses From TALAPRO-1 Trial |
| Niven Mehra, MD, Ph.D. |
| Niven Mehra presented results of the TALAPRO-1 safety profile of talazoparib in men with mCRPC with the aim of understanding how patients with adverse events were managed during the trial. The demonstrated safety profile, combined with the observed durable antitumor activity, supports further evaluation of talazoparib in advanced prostate cancer. There are 2 ongoing phase 3 trials: TALAPRO-2 comparing talazoparib plus enzalutamide with enzalutamide monotherapy as a first-line treatment in men with mCRPC with or without HRR gene alterations, and TALAPRO-3 in men with metastatic castration sensitive prostate cancer with HRR alterations. |
|
|
|
|
|
|
|
| To view our full coverage of the 2021 ASCO Annual Meeting, visit the Conference Coverage section on UroToday.com |
|
|
|
|
|
 |
|
|
|
|
